Literature DB >> 32359768

Dialysis Independence Following Combination Daratumumab, Thalidomide, Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma With Severe Renal Failure.

Donald C Moore1, Justin R Arnall2, Amanda Janes3, Mauricio Pineda-Roman3.   

Abstract

Entities:  

Keywords:  Daratumumab; Hemodialysis; Monoclonal antibody; Multiple myeloma; Renal impairment

Year:  2020        PMID： 32359768     DOI： 10.1016/j.clml.2020.03.014

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  2 in total

1.  Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.

Authors:  Shinichi Mizuno; Chigusa Kitayama; Shigeto Mashiko; Satoru Sanada
Journal:  CEN Case Rep       Date:  2021-11-24

2.  Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.

Authors:  Marcelo Capra; Thomas Martin; Philippe Moreau; Ross Baker; Ludek Pour; Chang-Ki Min; Xavier Leleu; Mohamad Mohty; Marta Reinoso Segura; Mehmet Turgut; Richard LeBlanc; Marie-Laure Risse; Laure Malinge; Sandrine Schwab; Meletios Dimopoulos
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.